Sequentia Biotech awarded the EIC Accelerator funding for MICK, its translational microbiome platform

Sequentia Biotech has just kicked off a two-year project co-financed by the European Innovation Council Accelerator program to advance and bring to market MICK, the first digital decision support platform helping healthcare professionals integrating microbiome analysis into clinical practice.


MICK and the benefits of Microbiome analysis for society

MICK is an all-in-one, cloud-based human microbiome analysis platform for healthcare. It provides automated, real-time, and accessible insights on the patient’s microbiome health status thus delivering evidence-based and patient specific recommendations to support the clinical decision-making process.

MICK sets a big step forward in the detection and monitoring of microbiome imbalance statuses – dysbiosis – which represent a risk factor for the genesis and evolution of a plethora of chronic diseases and pathologies. MICK will make microbiome analysis among healthcare practitioners accessible and as a consequence strongly increase access to targeted preventive medicine for citizens.

The EIC Accelerator program will help MICK becoming the reference software solution for microbiome analysis in Europe, by providing accurate, accessible, and affordable access to improve health outcomes to its citizens.


About the EIC Accelerator 

The European Innovation Council is Europe’s flagship innovation programme to identify, develop and scale up breakthrough technologies and game changing innovations. The EIC Accelerator aims to support companies (SMEs, start-ups, and spin-outs) to bring their innovations to market and scale up. It provides a mix of grant support and direct equity investments in companies through a dedicated EIC Fund, which also provides a platform for co-investments with other investors.

Sequentia Biotech is deeply honoured to be among the awarded companies to reveice funding from this competitive program.